Telitacicept not checked

Vor Biopharma · RC18 · RC18-L

FollowEvery change as it happens, and a Monday email
Stage
in China
Next date
Phase 3 trial completes
Trials
2 active
4 in total · 4 in the EU
Targets
 

What this is

How it works
A decoy protein that soaks up a signal molecule before it can reach the body's cells.-cept: receptor molecules, native or modified WHO name stem
Tested for
Generalized Myasthenia Gravis, Primary Sjogren's Disease
Main trialPhase 3
“The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.”In the company’s words, NCT06456580 on ClinicalTrials.gov
Other names
RC18 · RC18-L

Other drugs for Generalized Myasthenia Gravis

All 37 drugs for Generalized Myasthenia Gravis

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Mar 2027 A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Phase 3Recruiting Dec 2028 Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Phase 3Withdrawn 2 Jan 2025 A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
Phase 3Terminated 6 Jan 2025 A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Telitacicept

Following is part of Solo: you see every change to Telitacicept the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in